DeepMed Research

Insmed

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: 912

Market Cap: $13.2B

Website

Introduction: Insmed, Inc. is a global biopharmaceutical company, which engages in the development and commercialization of therapies for patients with rare diseases. Its focuses on Brensocatib, and Treprostinil Palmitil Inhalation Powder (TPIP) pipeline. The company was founded in 1988 and is headquartered in Bridgewater, NJ.

Clinical Trials

A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Treprostinil Palmitil Inhalation Powder in Participants With Pulmonary Arterial Hypertension

Phase 2

Completed

Conditions: Pulmonary Arterial Hypertension

Interventions: Drug: Treprostinil Palmitil
Drug: Placebo

First Posted Date: 2021-12-07

Last Posted Date: 2025-04-10

Lead Sponsor: Insmed Incorporated

Target Recruit Count: 102

Registration Number: NCT05147805

Locations: 🇦🇷
ARG001, Córdoba, Argentina
🇧🇪
BEL001, Liège, Belgium
🇯🇵
JPN009, Nagasaki-Shi, Nagasaki, Japan

and more 89 locations

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Brensocatib Tablets in Adults With Cystic Fibrosis

Phase 2

Completed

Conditions: Cystic Fibrosis

Interventions: Drug: Brensocatib
Drug: Placebo

First Posted Date: 2021-10-25

Last Posted Date: 2023-11-01

Lead Sponsor: Insmed Incorporated

Target Recruit Count: 29

Registration Number: NCT05090904

Locations: 🇺🇸
USA001, Gainesville, Florida, United States
🇺🇸
USA016, Augusta, Georgia, United States
🇺🇸
USA006, Cleveland, Ohio, United States

and more 11 locations

A Study of Treprostinil Palmitil Inhalation Powder (TPIP) In Pulmonary Arterial Hypertension (PAH)

Phase 2

Terminated

Conditions: Pulmonary Arterial Hypertension

Interventions: Drug: Treprostinil Palmitil

First Posted Date: 2021-03-10

Last Posted Date: 2023-09-22

Lead Sponsor: Insmed Incorporated

Target Recruit Count: 1

Registration Number: NCT04791514

Locations: 🇺🇸
USA002, New York, New York, United States

Study to Evaluate ALIS (Amikacin Liposome Inhalation Suspension) in Participants With Nontuberculous Mycobacterial Lung Infection Caused by Mycobacterium Avium Complex

Phase 3

Active, not recruiting

Conditions: Mycobacterium Infections, Nontuberculous

Interventions: Drug: ALIS
Drug: Azithromycin
Drug: Ethambutol
Drug: ELC (matching placebo for ALIS)

First Posted Date: 2020-12-21

Last Posted Date: 2025-04-23

Lead Sponsor: Insmed Incorporated

Target Recruit Count: 425

Registration Number: NCT04677569

Locations: 🇬🇧
GBR004, Liverpool, United Kingdom
🇬🇧
GBR007, London, United Kingdom
🇬🇧
GBR010, London, United Kingdom

and more 255 locations

Validation of Patient Reported Outcome Measures in Participants With Nontuberculous Mycobacterial Lung Infection Caused by Mycobacterium Avium Complex

Phase 3

Completed

Conditions: Mycobacterium Infections, Nontuberculous

Interventions: Drug: ALIS
Drug: Azithromycin
Drug: ELC
Drug: Ethambutol

First Posted Date: 2020-12-21

Last Posted Date: 2024-06-28

Lead Sponsor: Insmed Incorporated

Target Recruit Count: 99

Registration Number: NCT04677543

Locations: 🇪🇸
ESP002, Barcelona, Spain
🇪🇸
ESP004, Madrid, Spain
🇪🇸
ESP003, Barcelona, Spain

and more 59 locations

A Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib in Participants With Non-Cystic Fibrosis Bronchiectasis

Phase 3

Completed

Conditions: Non-Cystic Fibrosis Bronchiectasis

Interventions: Drug: Placebo
Drug: Brensocatib 10 mg
Drug: Brensocatib 25 mg

First Posted Date: 2020-10-20

Last Posted Date: 2024-11-12

Lead Sponsor: Insmed Incorporated

Target Recruit Count: 1767

Registration Number: NCT04594369

Locations: 🇺🇸
USA039, Kissimmee, Florida, United States
🇺🇸
USA029, Newport Beach, California, United States
🇺🇸
USA103, Plantation, Florida, United States

and more 370 locations

Study of Dose Escalation of Liposomal Amikacin for Inhalation (ARIKAYCE™) - Extension Phase

Phase 2

Completed

Conditions: Cystic Fibrosis

Interventions: Drug: Arikayce™

First Posted Date: 2019-04-05

Last Posted Date: 2020-07-30

Lead Sponsor: Insmed Incorporated

Target Recruit Count: 49

Registration Number: NCT03905642

Assessment of INS1007 in Participants With Non-Cystic Fibrosis Bronchiectasis

Phase 2

Completed

Conditions: Non-Cystic Fibrosis Bronchiectasis

Interventions: Drug: Brensocatib 25 mg
Drug: Placebo
Drug: Brensocatib 10 mg

First Posted Date: 2017-07-17

Last Posted Date: 2023-03-27

Lead Sponsor: Insmed Incorporated

Target Recruit Count: 256

Registration Number: NCT03218917

Locations: 🇧🇬
MHAT "Dr IvanSeliminski"-Sliven, Sliven, Bulgaria
🇧🇬
Cardioart Medical Center, Stara Zagora, Bulgaria
🇩🇰
Sjællands Universitetshospital, Roskilde, Roskilde, Denmark

and more 105 locations

Open-label Safety Extension Study Assessing Safety and Tolerability of LAI in Patients Who Participated in Study INS-212

Phase 3

Completed

Conditions: NTM Lung Infection Due to MAC

Interventions: Drug: LAI 590 mg
Drug: Multi-drug regimen

First Posted Date: 2015-12-11

Last Posted Date: 2020-02-10

Lead Sponsor: Insmed Incorporated

Target Recruit Count: 163

Registration Number: NCT02628600

Study to Evaluate Efficacy of LAI When Added to Multi-drug Regimen Compared to Multi-drug Regimen Alone

Phase 3

Completed

Conditions: Mycobacterium Infections, Nontuberculous

Interventions: Drug: LAI (Liposomal Amikacin for Inhalation) 590 mg

First Posted Date: 2015-01-22

Last Posted Date: 2020-05-07

Lead Sponsor: Insmed Incorporated

Target Recruit Count: 336

Registration Number: NCT02344004

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy